Crestwood Advisors Group LLC Has $380,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Crestwood Advisors Group LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN) by 18.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,804 shares of the company’s stock after buying an additional 888 shares during the quarter. Crestwood Advisors Group LLC’s holdings in AstraZeneca were worth $380,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in AZN. Swedbank AB grew its position in AstraZeneca by 1.3% in the third quarter. Swedbank AB now owns 2,705,757 shares of the company’s stock worth $210,806,000 after acquiring an additional 35,000 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in AstraZeneca by 268.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 60,624 shares of the company’s stock worth $4,723,000 after acquiring an additional 44,189 shares in the last quarter. Allworth Financial LP grew its position in AstraZeneca by 6.0% in the third quarter. Allworth Financial LP now owns 11,307 shares of the company’s stock worth $881,000 after acquiring an additional 637 shares in the last quarter. Arkadios Wealth Advisors grew its position in AstraZeneca by 174.9% in the third quarter. Arkadios Wealth Advisors now owns 12,762 shares of the company’s stock worth $994,000 after acquiring an additional 8,120 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in AstraZeneca by 3.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 191,741 shares of the company’s stock worth $14,939,000 after acquiring an additional 5,589 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an “overweight” rating for the company. UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

NASDAQ AZN opened at $75.40 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $69.09 and a 200 day simple moving average of $73.08. The company has a market cap of $233.83 billion, a P/E ratio of 33.36, a P/E/G ratio of 1.42 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $62.75 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be given a dividend of $1.03 per share. The ex-dividend date is Friday, February 21st. This represents a dividend yield of 2%. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s dividend payout ratio (DPR) is 91.15%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.